ReviewNature2025
Fungal impacts on Earth's ecosystems.
Review in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Assays of Antifungal Activity of an Antimicrobial Peptide Against Botrytis cinerea.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Pathogenicity and virulence of the blast fungusVirulence · 2026Review
- Synergistic antifungal activity and mechanisms of dehydronuciferine combined with fluconazole against drug-resistantMicrobiology spectrum · 2026Article
- Are novel and co-xenic associations common in alien fungal and fungus-like plant pathogens?The New phytologist · 2026Article
- The Origin and Early Evolution of Fungi: Challenges, Inferences, and Principles.Annual review of cell and developmental biology · 2026Review
- A human cell-free translation screen identifies the NT-2 mycotoxin as a ribosomal inhibitor that binds the peptidyl transferase center.Communications biology · 2026Article
- Biostimulant Modulation of Soil Mycobiome Structure and Diversity andMolecules (Basel, Switzerland) · 2026Article
- A Review of the Therapeutic Challenges and Novel Treatment Options in Mitigating Invasive Mycosis Associated withJournal of fungi (Basel, Switzerland) · 2026Review
- Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The repertoire of yeast species from human clinical samples in the United Kingdom 2016-2022: epidemiology, clinical relevance, and fluconazole resistance.Microbiology spectrum · 2026Article
- Dual-Targeting, Hybrid Antifungal Agents Targeting Candida albicans-An Overview.Chemical biology & drug design · 2026Review
- CRISPRi screening reveals essential fungal vulnerabilities.Nature microbiology · 2026Article
- Cost-Effective Solid-State NMR Of Fungal Glucans: A Case Study On Schizosaccharomyces pombe.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Atmospheric Pressure Dielectric Barrier Discharge Plasma Treatment ofMolecules (Basel, Switzerland) · 2026Article
- Innovation in antifungal therapy.EMBO molecular medicine · 2026Review
- Chromosome-Level Genome Assembly and Annotation of theJournal of fungi (Basel, Switzerland) · 2026Article
- Endophytic and ectomycorrhizal, an overlooked dual ecological niche? Insights from natural environments and Russula species.The New phytologist · 2026Article
- Compromising UDP-sugar nucleotide biosynthesis attenuatesCell surface (Amsterdam, Netherlands) · 2026Article
- Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.npj antimicrobials and resistance · 2026Review
- Fungal diversity, ecology and functions in soil ecosystems.Nature reviews. Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
Over the past billion years, the fungal kingdom has diversified to more than two million species, with over 95% still undescribed. Beyond the well-known macroscopic mushrooms and microscopic yeast, fungi are heterotrophs that feed on almost any organic carbon, recycling nutrients through the decay of dead plants and animals and sequestering carbon into Earth's ecosystems. Human-directed applications of fungi extend from leavened bread, alcoholic beverages and biofuels to pharmaceuticals, including antibiotics and psychoactive compounds. Conversely, fungal infections pose risks to ecosystems ranging from crops to wildlife to humans; these risks are driven, in part, by human and animal movement, and might be accelerating with climate change. Genomic surveys are expanding our knowledge of the true biodiversity of the fungal kingdom, and genome-editing tools make it possible to imagine harnessing these organisms to fuel the bioeconomy. Here, we examine the fungal threats facing civilization and investigate opportunities to use fungi to combat these threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.